Sexual Medicine Journal Now Published Online
We're pleased to announce that the ISSM's new open access journal, Sexual Medicine, is now ready to read online.
Two articles are now available and three more are in production, along with an introductory editorial from journal editor, Alan W. Shindel, MD.
Sexual Medicine is a peer-reviewed, open access journal featuring multidisciplinary clinical and basic research in all areas of global sexual medicine. The journal particularly acts as a venue for topics of regional or sub-specialty interest.
The Editorial Board of Sexual Medicine and the International Society for Sexual Medicine (ISSM) invite you to submit your manuscript.
Please click here to start reading!
App and Mobile Website Available for International Symposium on Prostate, Androgens and Men’s Sexual Health
Attendees of the International Symposium on Prostate, Androgens and Men’s Sexual Health, which begins today in Berlin, can use a mobile app to access meeting information.
The app, available for Android and iOS, offers full information on the scientific program, speakers and chairs, and travel and accessibility. Abstracts and the floorplan of the meeting venue are also included.
The app can be accessed with the following steps:
-
Go to either the App Store (Apple) or the Google Play Store (Android). You may also search for "Status Plus" manually.
-
Download and install the app.
-
Select the symposium in the "Available Events" section.
-
Tap the "Install Event" button to download all content.
At this point, all content is stored locally on your device and can be accessed without an internet connection.
You may also see the complete program on our mobile website.
BEGONIA Trial Examines Flibanserin for HSDD
Taking 100 mg of flibanserin once daily at bedtime may help premenopausal women with hypoactive sexual desire disorder (HSDD), a recent trial has found.
The trial, known as BEGONIA, involved over a thousand women with HSDD, a condition marked by low sex drive. HSDD causes personal distress and cannot be explained by another medical condition or a medication.
The women's mean age was 36.6 years and each participant had been in a heterosexual relationship for at least one year.
About half the women were randomly assigned to take flibanserin; the other half took a placebo. The trial lasted 24 weeks.
Levels of sexual desire, satisfaction, and distress were measured with several questionnaires, including the Female Sexual Function Index.
In addition, each woman submitted a daily electronic diary entry to report on sexually satisfying events (SSE). Sexual events were defined as instances of intercourse, oral sex, masturbation, or genital stimulation by a partner.
Women who took flibanserin had increases in sexual desire and number of SSEs when compared to the placebo group. Their overall function and levels of distress also improved.
The most common side effects were drowsiness, dizziness, and nausea. About 10% of the women in the flibanserin group and 4% of the placebo group left the study because of adverse events.
The study was published online in May in the Journal of Sexual Medicine. To learn more, please click here.
|
